AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31782193 — intervention group
Group type: COMPARATOR
Intervention: Improvised Nasal Atomizer (AT) kit
Number of subjects: 207
Study 31188825 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management intervention in addition to usual care
Number of subjects: 495
Study 31188825 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 495
Study 27243353 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% hyaluronic acid artificial tear (Visaid 0.3%)
Number of subjects: 16
Study 27243353 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (0.9% NaCl)
Number of subjects: 16
Study 26357896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 100
Study 26357896 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 100
Study 24111258 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) features
Number of subjects: 0
Study 24111258 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) features
Number of subjects: 0
Study 24111258 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-on-task (TOT) influence on WKL classification
Number of subjects: 0
Study 21218388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidant supplementation at nutritional doses
Number of subjects: 105
Study 21218388 — intervention group
Group type: COMPARATOR
Intervention: No antioxidant supplementation (Control)
Number of subjects: 105
Study 21218388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (supplementation and control)
Number of subjects: 105
Study 19335382 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO-Five Well-Being Index (WHO-5-T)
Number of subjects: 300
Study 17535867 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy for 6 months
Number of subjects: 12
Study 17535867 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-related controls
Number of subjects: 12
Study 16136168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-timing induction therapy followed by matched related donor allogeneic transplantation
Number of subjects: 1903
Study 16136168 — intervention group
Group type: COMPARATOR
Intervention: Standard-timing induction therapy
Number of subjects: 1903
Study 12115358 — intervention group
Group type: EXPERIMENTAL
Intervention: BRI-based prophylaxis strategy
Number of subjects: 512
Study 12115358 — intervention group
Group type: COMPARATOR
Intervention: Platelet threshold strategy of 20,000 per microL
Number of subjects: 512
Study 12115358 — intervention group
Group type: COMPARATOR
Intervention: Platelet threshold strategy of 10,000 per microL
Number of subjects: 512
Study 10195532 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg meperidine
Number of subjects: 45
Study 10195532 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg meperidine
Number of subjects: 45
Study 10195532 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg/kg meperidine
Number of subjects: 45
Study 10195532 — intervention group
Group type: COMPARATOR
Intervention: All doses
Number of subjects: 45
Study 7539668 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (filgrastim) 10 micrograms/kg/day
Number of subjects: 54
Study 7539668 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (filgrastim) 30 micrograms/kg/day
Number of subjects: 54
Study 7539668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no growth factor)
Number of subjects: 54
Study 2405108 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 via splenic artery infusion
Number of subjects: 28
Study 2405108 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 via hepatic artery infusion
Number of subjects: 28
Study 7288433 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin infusion (2.1 mg/min for 4 hours)
Number of subjects: 4
Study 7288433 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 4
Study 31776782 — intervention group
Group type: EXPERIMENTAL
Intervention: WLS Optimum (specialized multivitamin supplement)
Number of subjects: 139
Study 31776782 — intervention group
Group type: COMPARATOR
Intervention: sMVS (standard multivitamin supplement)
Number of subjects: 139
Study 31566579 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (DNA at M0, M1, M3, M6 with protein coadministered at M3 and M6)
Number of subjects: 104
Study 31566579 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 (protein and DNA coadministered at each vaccination visit)
Number of subjects: 104
Study 31566579 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 104
Study 31566579 — intervention group
Group type: EXPERIMENTAL
Intervention: T3
Number of subjects: 104
Study 31566579 — intervention group
Group type: EXPERIMENTAL
Intervention: T4
Number of subjects: 104
Study 31566579 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 104
Study 31566579 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 and T4
Number of subjects: 104
Study 26597394 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extremity mobilization and neuromuscular electrical stimulation (NMES)
Number of subjects: 30
Study 26597394 — intervention group
Group type: EXPERIMENTAL
Intervention: Only NMES
Number of subjects: 30
Study 26597394 — intervention group
Group type: EXPERIMENTAL
Intervention: Active extremity exercise training
Number of subjects: 30
Study 26597394 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 30
Study 26597394 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-1 (Active extremity mobilization and NMES)
Number of subjects: 30
Study 26597394 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-2 (Only NMES)
Number of subjects: 30
Study 25301760 — intervention group
Group type: COMPARATOR
Intervention: Control arm (long-term androgen deprivation therapy - ADT)
Number of subjects: 917
Study 23331559 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 100 mg
Number of subjects: 19
Study 23331559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22353410 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive cements (RMGIC+DBA)
Number of subjects: 100
Study 22353410 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive cements (RMGIC)
Number of subjects: 100
Study 22353410 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive cements (GIC)
Number of subjects: 100
Study 22353410 — intervention group
Group type: COMPARATOR
Intervention: Nonadhesive cements (ZP)
Number of subjects: 100
Study 22353410 — intervention group
Group type: COMPARATOR
Intervention: Nonadhesive cements (PC)
Number of subjects: 100
Study 19335674 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and weight training exercises for 24 months
Number of subjects: 110
Study 19335674 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no exercise)
Number of subjects: 110
Study 16400056 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg alpha-tocopherol/d
Number of subjects: 58
Study 16400056 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg mixed tocopherols/d
Number of subjects: 58
Study 16400056 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 58
Study 15380045 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT), calcium, and vitamin D3
Number of subjects: 88
Study 15380045 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D3 alone
Number of subjects: 88
Study 11673017 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 0
Study 11673017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 0
Study 11673017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 0
Study 11673017 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0
Study 11673017 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study 11673017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0
Study 11673017 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0
Study 11673017 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal Nerve Stimulation (VNS)
Number of subjects: 0
Study 9163286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 49
Study 9163286 — intervention group
Group type: COMPARATOR
Intervention: TIPS
Number of subjects: 49
Study 8217756 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin applied once daily for 40 weeks
Number of subjects: 38
Study 8217756 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied once daily for 40 weeks
Number of subjects: 38
Study 8217756 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin
Number of subjects: 38
Study 8217756 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 38
Study 3296861 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (phenprocoumon or acenocoumarol)
Number of subjects: 113
Study 3296861 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (phenprocoumon or acenocoumarol) plus pentoxifylline (800-1200 mg/day)
Number of subjects: 113
Study 3296861 — intervention group
Group type: COMPARATOR
Intervention: Irregular treatment with various vasodilators (xanthinolnicotinate, naftidrofuryl, pyridylmethanol, etc.)
Number of subjects: 113
Study 31982095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rater Training (RT)
Number of subjects: 47
Study 31982095 — intervention group
Group type: COMPARATOR
Intervention: No Training (Control)
Number of subjects: 47
Study 31982095 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized assessments (OSATS GRS)
Number of subjects: 47
Study 28961366 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst stimulation
Number of subjects: 100
Study 28961366 — intervention group
Group type: COMPARATOR
Intervention: Tonic stimulation
Number of subjects: 100
Study 26708108 — intervention group
Group type: COMPARATOR
Intervention: Placebo CBD (0 mg)
Number of subjects: 31
Study 26708108 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (200 mg)
Number of subjects: 31
Study 26708108 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (400 mg)
Number of subjects: 31
Study 26708108 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (800 mg)
Number of subjects: 31
Study 25688926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh kimchi
Number of subjects: 24
Study 25688926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented kimchi
Number of subjects: 24
Study 23523222 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane
Number of subjects: 54
Study 23523222 — intervention group
Group type: COMPARATOR
Intervention: Skin staples (control group)
Number of subjects: 54
Study 21640044 — intervention group
Group type: EXPERIMENTAL
Intervention: FIN-RACo combination therapy (methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone), n=69
Number of subjects: 129
Study 21640044 — intervention group
Group type: COMPARATOR
Intervention: Single DMARD therapy (initially sulfasalazine with or without prednisolone), n=60
Number of subjects: 129
Study 19920426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interscalene brachial plexus block with 10 mL of ropivacaine 0.75%
Number of subjects: 30
Study 19920426 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation interscalene brachial plexus block with 10 mL of ropivacaine 0.75%
Number of subjects: 30
Study 19920426 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation interscalene brachial plexus block
Number of subjects: 30
Study 16512478 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF/PGF ratio
Number of subjects: 0
Study 12734907 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 76
Study 12734907 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 76
Study 10943872 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg/day after a 3-day 100 mg/day loading dose)
Number of subjects: 39
Study 10943872 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (increased stepwise to 15 mg/week)
Number of subjects: 39
Study 10943872 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide and Methotrexate
Number of subjects: 39
Study 10943872 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide and Methotrexate (in subset fulfilling 20% response criteria)
Number of subjects: 39
Study 9301427 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (3 sessions a week, 60-80% of VO2max for 12 weeks followed by 14 weeks non-supervised)
Number of subjects: 58
Study 9301427 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 58
Study 9301427 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational programme)
Number of subjects: 58
Study 8330603 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.79 +/- 0.4 mg kg‐1 h‐1
Number of subjects: 30
Study 8330603 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.08 +/- 0.01 mg kg‐1 h‐1
Number of subjects: 30
Study 8330603 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone 1.8 +/- 0.2 mg kg‐1 h‐1
Number of subjects: 30
Study 8330603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sedative agent)
Number of subjects: 30
Study 3275752 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF) with endocrine treatment (prednisone, oophorectomy)
Number of subjects: 818
Study 3275752 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF)
Number of subjects: 818
Study 29401246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifastuzumab vedotin (LIFA) 2.4 mg/kg, intravenously, every 3 weeks (Q3W)
Number of subjects: 95
Study 29401246 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 40 mg/m2, intravenously, every 4 weeks (Q4W)
Number of subjects: 95
Study 29401246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifastuzumab vedotin (LIFA)
Number of subjects: 95
Study 29401246 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 95
Study 28453703 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive RT/CT (arm A)
Number of subjects: 161
Study 28453703 — intervention group
Group type: COMPARATOR
Intervention: Surgery (arm B)
Number of subjects: 161
Study 28453703 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartV5 influence
Number of subjects: 161
Study 28453703 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of death
Number of subjects: 161
Study 25306088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olive oil
Number of subjects: 100
Study 25306088 — intervention group
Group type: COMPARATOR
Intervention: Oral sunflower oil (control)
Number of subjects: 100
Study 23547492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride (SnF2) dentifrice
Number of subjects: 120
Study 23547492 — intervention group
Group type: COMPARATOR
Intervention: 0.3% triclosan dentifrice
Number of subjects: 120
Study 21417739 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care consultation
Number of subjects: 67
Study 18756586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 118
Study 18756586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 16492992 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer treatment
Number of subjects: 780
Study 16492992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 16492992 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal IQ <70
Number of subjects: 780
Study 16492992 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal IQ >=70
Number of subjects: 780
Study 12920628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment (400 IU/day for children <30 kg, 800 IU/day for children >30 kg)
Number of subjects: 55
Study 12920628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 55
Study 12920628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9885327 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbasalate (equivalent to 900 mg aspirin) plus metoclopramide 10 mg (CM)
Number of subjects: 296
Study 9885327 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine tartrate 1 mg plus caffeine 100 mg (EC)
Number of subjects: 296
Study 8933892 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S)
Number of subjects: 4
Study 8933892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (I)
Number of subjects: 4
Study 8933892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 4
Study 8933892 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous resolution (R)
Number of subjects: 4
Study 1991678 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Day Health Care (ADHC)
Number of subjects: 0
Study 1991678 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization and costs of health care
Number of subjects: 0
Study 7102707 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 percent acyclovir ointment
Number of subjects: 73
Study 7102707 — intervention group
Group type: COMPARATOR
Intervention: 3 percent vidarabine ointment
Number of subjects: 73
Study 31211178 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 220 mg b.i.d.
Number of subjects: 78
Study 31211178 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78
Study 28118410 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised invitation letter
Number of subjects: 13886
Study 28118410 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised invitation letter + informative leaflet
Number of subjects: 13886
Study 28118410 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised invitation letter + informative leaflet + personalised phone call
Number of subjects: 13886
Study 28118410 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous demand of cervical cancer screening)
Number of subjects: 13886
Study 26738271 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 or 25 mg/day)
Number of subjects: 0
Study 26738271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24382277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day)
Number of subjects: 0
Study 24382277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22103890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Brief Adlerian Psychodynamic Psychotherapy (SB-APP)
Number of subjects: 35
Study 22103890 — intervention group
Group type: COMPARATOR
Intervention: Supervised Team Management (STM)
Number of subjects: 35
Study 19480226 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent bedtime routine
Number of subjects: 405
Study 19480226 — intervention group
Group type: COMPARATOR
Intervention: Usual bedtime routine (Control)
Number of subjects: 405
Study 17718375 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 28
Study 15499953 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml 30% glucose in spray form
Number of subjects: 60
Study 15499953 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml 30% glucose by syringe
Number of subjects: 60
Study 15499953 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml sterile water by syringe
Number of subjects: 60
Study 11483910 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 44
Study 11483910 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 44
Study 11483910 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase women
Number of subjects: 44
Study 11483910 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase women
Number of subjects: 44
Study 9560127 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 169
Study 9560127 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 169
Study 7890017 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 0
Study 7890017 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric Diet (HD)
Number of subjects: 0
Study 2905154 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg twice daily
Number of subjects: 110
Study 2905154 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg twice daily
Number of subjects: 110
Study 2905154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 31156062 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV9 vaccination
Number of subjects: 395
Study 30489323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients without postoperative complications
Number of subjects: 100
Study 30489323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients with higher preoperative physical status
Number of subjects: 100
Study 30489323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in men
Number of subjects: 100
Study 30489323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients without postoperative stoma
Number of subjects: 100
Study 30489323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients with shorter time to readiness for discharge (≤4 days)
Number of subjects: 100
Study 30489323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients with shorter length of stay (≤4 days)
Number of subjects: 100
Study 30489323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores preoperatively
Number of subjects: 100
Study 30489323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores at 2 weeks postoperatively
Number of subjects: 100
Study 30489323 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores at 4 weeks postoperatively
Number of subjects: 100